A Transgenic Model of Visceral Obesity and the Metabolic Syndrome
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The adverse metabolic consequences of obesity are best predicted by the quantity of visceral fat. Excess glucocorticoids produce visceral obesity and diabetes, but circulating glucocorticoid levels are normal in typical obesity. Glucocorticoids can be produced locally from inactive 11-keto forms through the enzyme 11β hydroxysteroid dehydrogenase type 1 (11β HSD-1). We created transgenic mice overexpressing 11β HSD-1 selectively in adipose tissue to an extent similar to that found in adipose tissue from obese humans. These mice had increased adipose levels of corticosterone and developed visceral obesity that was exaggerated by a high-fat diet. The mice also exhibited pronounced insulin-resistant diabetes, hyperlipidemia, and, surprisingly, hyperphagia despite hyperleptinemia. Increased adipocyte 11β HSD-1 activity may be a common molecular etiology for visceral obesity and the metabolic syndrome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“other health outcomes associated with better quality of life improved, including sleep apnoea136 and mobility137.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [137]
Citations
Cites
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Kopelman, P. G. (2000) · Nature · doi:10.1038/35007508 · Cited by 4,795
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes
Scherer, P. E., Williams, S., Fogliano, M., Baldini, G., & Lodish, H. F. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.26746 · Cited by 3,237
Role of leptin in the neuroendocrine response to fasting
Ahima, R. S., Prabakaran, D., Mantzoros, C., Qu, D., Lowell, B., Maratos-Flier, E., & Flier, J. S. (1996) · Nature · doi:10.1038/382250a0 · Cited by 3,117
Self-citationSubcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961
Ahima, R. S., & Flier, J. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.413 · Cited by 1,428
Self-citationThe Degree of Masculine Differentiation of Obesities
VAGUE, J. (1956) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/4.1.20 · Cited by 1,410
Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver
Abel, E. D., Peroni, O., Kim, J. K., Kim, Y.-B., Boss, O., Hadro, E., Minnemann, T., Shulman, G. I., & Kahn, B. B. (2001) · Nature · doi:10.1038/35055575 · Cited by 1,253
Frühbeck, G., Gómez-Ambrosi, J., Muruzábal, F. J., & Burrell, M. A. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.6.e827 · Cited by 974
Research works printed but not linked: 5
- 10.1210/jcem.86.3.7453 · doi:10.1210/jcem.86.3.7453 · Paper page
- 10.1101/gad.7.7b.1318 · doi:10.1101/gad.7.7b.1318 · Paper page
- Supplementary data are available on Science Online at www.sciencemag.org/cgi/content/full/294/5549/2166/DC1.
- Strack A. M., Bradbury M. J., Dallman M. F., Am. J. Physiol. 268, R183 (1995).
- 10.1210/jcem.83.5.4951 · doi:10.1210/jcem.83.5.4951 · Paper page
Cited by
Items 101–200 of 1,003
The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome
Wang, M. (2005) · Nutrition & Metabolism · doi:10.1186/1743-7075-2-3 · Cited by 277
“Mice with adipose-specific overexpression of the rat 11β-HSD1 had increased adipose levels of corticosterone and acquired features of the Metabolic Syndrome: diet-induced visceral obesity, insulin resistance, hyperlipidemia and hyperphagia [151].”
Niskanen, L., Laaksonen, D. E., Punnonen, K., Mustajoki, P., Kaukua, J., & Rissanen, A. (2004) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1462-8902.2004.00335.x · Cited by 275
11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess
Morgan, S. A., McCabe, E. L., Gathercole, L. L., Hassan-Smith, Z. K., Larner, D. P., Bujalska, I. J., Stewart, P. M., Tomlinson, J. W., & Lavery, G. G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323681111 · Cited by 272
“Indeed, this was confirmed in the adipose-specific 11β-HSD1–overexpressing mice, where twofold higher intraadipose CORT levels were recorded in comparison with WT controls (9).”
BackgroundThe Role of Dairy Foods in Weight Management
Zemel, M. B. (2005) · Journal of the American College of Nutrition · doi:10.1080/07315724.2005.10719502 · Cited by 272
“Further, selective overexpression of 11- -HSD-1 in white adipose tissue of mice results in central obesity [53,54], while homozygous 11 -HSD-1 knockout mice exhibit protection from features of the metabolic syndrome [55].”
BackgroundBornstein, S. R., Schuppenies, A., Wong, M.-L., & Licinio, J. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001873 · Cited by 266
Andrews, R. C., Rooyackers, O., & Walker, B. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021194 · Cited by 266
“Conversely, mice with transgenic overexpression of 11 -HSD1 selectively in adipose tissue under the aP2 promoter have increased intraadipose glucocorticoid concentrations despite no change in plasma levels (5).”
BackgroundJohnson, P. J. (2002) · Veterinary Clinics of North America: Equine Practice · doi:10.1016/s0749-0739(02)00006-8 · Cited by 264
“In this regard, the accumulation of intra-abdominal, omental adipocytes is much more significant than adipocyte accumulations at other locations in the body [23,24].”
BackgroundInfluentialCaterson, I. D., Hubbard, V., Bray, G. A., Grunstein, R., Hansen, B. C., Hong, Y., Labarthe, D., Seidell, J. C., & Smith, S. C. (2004) · Circulation · doi:10.1161/01.cir.0000140114.83145.59 · Cited by 264
Alberts, P., Nilsson, C., Selén, G., Engblom, L. O. M., Edling, N. H. M., Norling, S., Klingström, G., Larsson, C., Forsgren, M., Ashkzari, M., et al. (2003) · Endocrinology · doi:10.1210/en.2003-0344 · Cited by 263
Fat as an Endocrine Organ: Relationship to the Metabolic Syndrome
Hutley, L., & Prins, J. B. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200512000-00005 · Cited by 262
P., A., L., E., N., E., M., F., G., K., C., L., Y., R.-N., B., Ö., & L., A. (2002) · Diabetologia · doi:10.1007/s00125-002-0959-6 · Cited by 259
Adipokines: implications for female fertility and obesity
Mitchell, M., Armstrong, D. T., Robker, R. L., & Norman, R. J. (2005) · Reproduction · doi:10.1530/rep.1.00521 · Cited by 259
“…2002, Lee et al. 2005) but adipose mRNA resistin levels are generally lower or unchanged in these models (Juan et al. 2001, Le Lay et al. 2001, Masuzaki et al. 2001, Way et al. 2001, Milan et al. 2002, Lee et al. 2005), which may be explained by altered translational or post-translational…”
BackgroundObesity-Initiated Metabolic Syndrome and the Kidney: A Recipe for Chronic Kidney Disease?
Bagby, S. P. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000141965.28037.ee · Cited by 257
“Supporting the relevance of locally generated glucocorticoid in WAT, transgenic mice overexpressing 11 HSD1 in adipocytes faithfully reproduced the metabolic syndrome (67,68), whereas deficient mice were metabolically resistant to high-fat feeding (69).”
BackgroundFresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions
Li, J.-X., & Cummins, C. L. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00683-6 · Cited by 257
The adipocyte as an active participant in energy balance and metabolism
Badman, M. K., & Flier, J. S. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.058 · Cited by 256
Self-citationAdipocyte-Specific Glucocorticoid Inactivation Protects Against Diet-Induced Obesity
Kershaw, E. E., Morton, N. M., Dhillon, H., Ramage, L., Seckl, J. R., & Flier, J. S. (2005) · Diabetes · doi:10.2337/diabetes.54.4.1023 · Cited by 253
“11 HSD1 is decreased in liver and enhanced in mesenteric adipose tissue (MAT) in several models of rodent obesity, including leptin-resistant Lepr/ Lepr rats (8,9) and leptin-deficient Lep/Lep mice (10).”
BackgroundSelf-citationEffects of Chronic Social Stress on Obesity
Scott, K. A., Melhorn, S. J., & Sakai, R. R. (2012) · Current Obesity Reports · doi:10.1007/s13679-011-0006-3 · Cited by 251
“Additionally, the ability to look at the effects of down- or upregulation of gene expression via spontaneous mutations, transgenics, and the use of viral vectors yields invaluable information on genetic vulnerability or resilience to disease [61–65].”
BackgroundGlucocorticoid receptor variants: clinical implications
DeRijk, R. H., Schaaf, M., & de Kloet, E. R. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(02)00062-6 · Cited by 251
Obstructive Sleep Apnea Syndrome Is Associated With Some Components of Metabolic Syndrome
Kono, M., Tatsumi, K., Saibara, T., Nakamura, A., Tanabe, N., Takiguchi, Y., & Kuriyama, T. (2007) · Chest · doi:10.1378/chest.06-1807 · Cited by 250
Complex Role of the Vitamin D Receptor and Its Ligand in Adipogenesis in 3T3-L1 Cells
Blumberg, J. M., Tzameli, I., Astapova, I., Lam, F. S., Flier, J. S., & Hollenberg, A. N. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510343200 · Cited by 250
Self-citationLodhi, I. J., Yin, L., Jensen-Urstad, A. P. L., Funai, K., Coleman, T., Baird, J. H., El Ramahi, M. K., Razani, B., Song, H., Fu-Hsu, F., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.06.013 · Cited by 246
“Consistent with the observation that decreased adiposity improves insulin sensitivity in numerous animal models (Elchebly et al., 1999; Masuzaki et al., 2001; Yang et al., 2005; Yuan et al., 2001), levels of phospho-Akt relative to total Akt were increased in skeletal muscle of HFD-fed FASKOF mice…”
Background11β-Hydroxysteroid dehydrogenases and the brain: From zero to hero, a decade of progress
Wyrwoll, C. S., Holmes, M. C., & Seckl, J. R. (2011) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2010.12.001 · Cited by 244
“els of corticosterone [206], nor does overexpression in fat [164] or the brain [102].”
Self-citationAdipose Tissue and Adipokines—Energy Regulation from the Human Perspective
Trayhurn, P., Bing, C., & Wood, I. S. (2006) · The Journal of Nutrition · doi:10.1093/jn/136.7.1935s · Cited by 242
Paulmyer-Lacroix, O., Boullu, S., Oliver, C., Alessi, M.-C., & Grino, M. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8614 · Cited by 241
Bispham, J., Gopalakrishnan, G. S., Dandrea, J., Wilson, V., Budge, H., Keisler, D. H., Broughton Pipkin, F., Stephenson, T., & Symonds, M. E. (2003) · Endocrinology · doi:10.1210/en.2003-0320 · Cited by 240
Glucocorticoids and 11beta-Hydroxysteroid Dehydrogenase in Adipose Tissue
Seckl, J. R. (2004) · Recent Progress in Hormone Research · doi:10.1210/rp.59.1.359 · Cited by 239
“aP2–11 -HSD1 transgenic mice show adipocyte hypertrophy but not hyperplasia (Masuzaki et al., 2001).”
InfluentialSelf-citationTataranni, P. A., & Ortega, E. (2005) · Diabetes · doi:10.2337/diabetes.54.4.917 · Cited by 238
Swarbrick, M. M., & Havel, P. J. (2008) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2007.0029 · Cited by 238
“169 Conversely, knockout of 11 (cid:4) HSD-1 in all tissues was associated with increased adiponectin mRNA expression in epididymal fat, although not in visceral mesenteric fat.”
The Biological Actions of Dehydroepiandrosterone Involves Multiple Receptors
Webb, S. J., Geoghegan, T. E., Prough, R. A., & Michael Miller, K. K. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600569877 · Cited by 237
“Transgenic mice over-expressing 11β-HSD1 in adipocytes show signs of central obesity, hyperlipidemia, hyperglycemia, and insulin resistance, similar to the symptoms of metabolic syndrome in humans (Masuzaki et al., 2001).”
BackgroundSystemic Glucocorticoid Therapy: a Review of its Metabolic and Cardiovascular Adverse Events
Fardet, L., & Fève, B. (2014) · Drugs · doi:10.1007/s40265-014-0282-9 · Cited by 236
“11BHSD1 overexpression in mouse adipose tissue leads to an increase of triacylglycerol and cholesterol plasma levels [80], while 11BHSD1 overexpression in liver provokes insulin resistance, hepatic steatosis, and disturbed lipid synthesis [81].”
BackgroundHirata, A., Maeda, N., Hiuge, A., Hibuse, T., Fujita, K., Okada, T., Kihara, S., Funahashi, T., & Shimomura, I. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp191 · Cited by 236
“In fact, the adipose 11b-HSD1 and glucocorticoid action is closely associated with the development of obesity and metabolic syndrome.(31,32) The MR binds not only aldosterone but also glucocorticoid with equal affinity.”
BackgroundKatagiri, H., Yamada, T., & Oka, Y. (2007) · Circulation Research · doi:10.1161/circresaha.107.151621 · Cited by 235
Cortisol on Circadian Rhythm and Its Effect on Cardiovascular System
Mohd Azmi, N. A. S., Juliana, N., Azmani, S., Mohd Effendy, N., Abu, I. F., Mohd Fahmi Teng, N. I., & Das, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18020676 · Cited by 232
“Elevated 11β-HSD1 activity can be seen in patients with these conditions [106].”
BackgroundConvertible visceral fat as a therapeutic target to curb obesity
Giordano, A., Frontini, A., & Cinti, S. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.31 · Cited by 232
Wake, D. J., Rask, E., Livingstone, D. E. W., Söderberg, S., Olsson, T., & Walker, B. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030286 · Cited by 231
Approach to the Pathogenesis and Treatment of Nonalcoholic Steatohepatitis
Medina, J., Fernández-Salazar, L. I., García-Buey, L., & Moreno-Otero, R. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2057 · Cited by 229
Adipogenic and lipolytic effects of chronic glucocorticoid exposure
Campbell, J. E., Peckett, A. J., D'souza, A. M., Hawke, T. J., & Riddell, M. C. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00045.2010 · Cited by 228
“In adipose tissue, elevating 11 HSD1 activity increases the concentration of Cort up to 15-fold over the levels found in the circulation (19).”
BackgroundMethodInfluentialAnatomical Patterning of Visceral Adipose Tissue: Race, Sex, and Age Variation
Demerath, E. W., Sun, S. S., Rogers, N., Lee, M., Reed, D., Choh, A. C., Couch, W., Czerwinski, S. A., Chumlea, W. C., Siervogel, R. M., et al. (2007) · Obesity · doi:10.1038/oby.2007.356 · Cited by 228
“Discussion Despite the fundamental involvement of central (abdominal) adiposity in the etiology of diabetes and coronary heart disease (29,30), there is no consensus on a standardized method for its measurement, perhaps because the complexity of adipose tissue endocrinology and metabolism has only recently been apprec…”
BackgroundThe Underlying Basis for Obesity: Relationship to Cancer
Bray, G. A. (2002) · The Journal of Nutrition · doi:10.1093/jn/132.11.3451s · Cited by 227
“A transgenic model in which this enzyme is overexpressed has increased deposition of visceral fat, lending credence to this hypothesis (30).”
BackgroundThe Human Obesity Gene Map: The 2002 Update
Chagnon, Y. C., Rankinen, T., Snyder, E. E., Weisnagel, S. J., Pérusse, L., & Bouchard, C. (2003) · Obesity Research · doi:10.1038/oby.2003.47 · Cited by 226
“1 Hsd11b1 Tg; obesity 1q32-q41 HSD11B1 Hydroxysteroid (11-beta) dehydrogenase 1 (286)”
Lindsay, R. S., Wake, D. J., Nair, S., Bunt, J., Livingstone, D. E. W., Permana, P. A., Tataranni, P. A., & Walker, B. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-030017 · Cited by 225
Social factors and individual vulnerability to chronic stress exposure
Bartolomucci, A., Palanza, P., Sacerdote, P., Panerai, A. E., Sgoifo, A., Dantzer, R., & Parmigiani, S. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.06.009 · Cited by 225
Adipose Tissue: Physiology to Metabolic Dysfunction
Richard, A. J., White, U. A., Elks, C. M., & Stephens, J. M. (2020) · Europe PMC (PubMed Central) · Cited by 224
Protein-Mediated Fatty Acid Uptake: Novel Insights from In Vivo Models
Doege, H., & Stahl, A. (2006) · Physiology · doi:10.1152/physiol.00014.2006 · Cited by 222
“51, 78). Because of the physiological significance of LCFAs, chronic imbalances in lipid fluxes and metabolism often cause a variety of (metabolic) abnormalities and pathologies, including hyperlipidemia, obesity, Type 2 diabetes mellitus, nonalcoholic fatty liver disease, heart disease, and cancer (16, 37, 50, 54, 56…”
BackgroundMedical Sequencing at the Extremes of Human Body Mass
Ahituv, N., Kavaslar, N., Schackwitz, W., Ustaszewska, A., Martin, J., Hébert, S., Doelle, H., Ersoy, B., Kryukov, G., Schmidt, S., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/513471 · Cited by 221
Hoffmann, F., & Maser, E. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530600969440 · Cited by 221
“resulted in marked insulin resistance and hyperlipidemia (Masuzaki et al., 2001).”
BackgroundRole of visceral adipose tissue in aging
Huffman, D. M., & Barzilai, N. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.01.008 · Cited by 220
“When this enzyme was overexpressed in adipose tissue in mice, animals developed visceral obesity and diabetes [40].”
BackgroundDexamethasone induction of hypertension and diabetes is PPAR-α dependent in LDL receptor–null mice
Bernal-Mizrachi, C., Weng, S., Feng, C., Finck, B. N., Knutsen, R. H., Leone, T. C., Coleman, T., Mecham, R. P., Kelly, D. P., & Semenkovich, C. F. (2003) · Nature Medicine · doi:10.1038/nm898 · Cited by 212
“Local production of active glucocorticoids in critical tissues promotes insulin resistanc”
BackgroundRegulation of 11β‐HSD Genes in Human Adipose Tissue: Influence of Central Obesity and Weight Loss
Engeli, S., Böhnke, J., Feldpausch, M., Gorzelniak, K., Heintze, U., Janke, J., Luft, F. C., & Sharma, A. M. (2004) · Obesity Research · doi:10.1038/oby.2004.3 · Cited by 211
Aneja, A. (2004) · Recent Progress in Hormone Research · doi:10.1210/rp.59.1.169 · Cited by 209
“A transgenic mouse that overexpresses the cortisol-forming enzyme 11-hydroxysteroid dehydrogenase (HSD) 1 develops obesity hypertension and all features of the metabolic syndrome (Masuzaki et al., 2001).”
Guerre-Millo, M. (2002) · Journal of Endocrinological Investigation · doi:10.1007/bf03344048 · Cited by 209
Lavery, G. G., Walker, E. A., Draper, N., Jeyasuria, P., Marcos, J., Shackleton, C. H. L., Parker, K. L., White, P. C., & Stewart, P. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512635200 · Cited by 207
Opherk, C., Tronche, F., Kellendonk, C., Kohlmüller, D., Schulze, A., Schmid, W., & Schütz, G. (2004) · Molecular Endocrinology · doi:10.1210/me.2003-0283 · Cited by 207
Kaserer, T., Beck, K., Akram, M., Odermatt, A., & Schuster, D. (2015) · Molecules · doi:10.3390/molecules201219880 · Cited by 207
Kannisto, K., Pietiläinen, K. H., Ehrenborg, E., Rissanen, A., Kaprio, J., Hamsten, A., & Yki-Järvinen, H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0153 · Cited by 205
Sandeep, T. C., Andrew, R., Homer, N. Z. M., Andrews, R. C., Smith, K., & Walker, B. R. (2005) · Diabetes · doi:10.2337/diabetes.54.3.872 · Cited by 205
“Transgenic mice that overexpress 11HSD1 by approximately threefold selectively in adipocytes under the AP2 promoter/enhancer (2,3) develop about a twofold increase in intraadipose glucocorticoid levels despite no change in plasma levels, which are controlled by a compensatory fall in ACTH secretion.”
BackgroundThe Physiology of Cellular Liporegulation
Unger, R. H. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142622 · Cited by 205
Obesity I: Overview and molecular and biochemical mechanisms
Lustig, R. H., Collier, D., Kassotis, C., Roepke, T. A., Kim, M. J., Blanc, E., Barouki, R., Bansal, A., Cave, M. C., Chatterjee, S., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115012 · Cited by 203
Demerath, E. W., Reed, D., Rogers, N., Sun, S. S., Lee, M., Choh, A. C., Couch, W., Czerwinski, S. A., Chumlea, W. C., Siervogel, R. M., et al. (2008) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26546 · Cited by 203
Cooper, M. S., Rabbitt, E. H., Goddard, P. E., Bartlett, W. A., Hewison, M., & Stewart, P. M. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.6.979 · Cited by 200
“This hypothesis has been supported by the development of a viscerally obese phenotype in mice with targeted overexpression of 11 -HSD1 in adipose tissue.((31)) Furthermore, these mice had increased levels of corticosterone in fat tissue, proving that 11 -HSD1 expression in vivo directly impacts on local glucocorticoid…”
BackgroundDiscrimination of Health Risk by Combined Body Mass Index and Waist Circumference
Ardern, C. I., Katzmarzyk, P. T., Janssen, I., & Ross, R. (2003) · Obesity Research · doi:10.1038/oby.2003.22 · Cited by 199
Abnormal Cortisol Metabolism and Tissue Sensitivity to Cortisol in Patients with Glucose Intolerance
Andrews, R. C., Herlihy, O., Livingstone, D. E. W., Andrew, R., & Walker, B. R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020048 · Cited by 199
Yokum, S., Ng, J., & Stice, E. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.175 · Cited by 199
Endocrinology of Adipose Tissue - An Update
Fischer-Posovszky, P., Wabitsch, M., & Hochberg, Z. (2007) · Hormone and Metabolic Research · doi:10.1055/s-2007-976539 · Cited by 198
11β-hydroxysteroid dehydrogenase 1: translational and therapeutic aspects
Gathercole, L. L., Lavery, G. G., Morgan, S. A., Cooper, M. S., Sinclair, A. J., Tomlinson, J. W., & Stewart, P. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1050 · Cited by 196
Koch, M. A., Wittenberg, L.-O., Basu, S., Jeyaraj, D. A., Gourzoulidou, E., Reinecke, K., Odermatt, A., & Waldmann, H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404719101 · Cited by 196
FAT CELLS: Afferent and Efferent Messages Define New Approaches to Treat Obesity
Lafontan, M. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095843 · Cited by 194
The renin angiotensin system and the metabolic syndrome
de Kloet, A. D., Krause, E. G., & Woods, S. C. (2010) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.03.018 · Cited by 194
Does altered glucocorticoid homeostasis increase cardiovascular risk?
GIROD, J., & BROTMAN, D. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.07.006 · Cited by 193
“[78] Masuzaki H, Paterson J, Shinyama H, et al.”
Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones
Geisler, C. E., & Renquist, B. J. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0513 · Cited by 191
Diagnosis, prevention, and intervention for the metabolic syndrome
Scott, C. L. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00507-1 · Cited by 191
Pathophysiology of Dyslipidemia in Cushing’s Syndrome
Arnaldi, G., Scandali, V. M., Trementino, L., Cardinaletti, M., Appolloni, G., & Boscaro, M. (2010) · Neuroendocrinology · doi:10.1159/000314213 · Cited by 189
“Interestingly, in transgenic mice, overexpression of 11βHSD1 in mature adipocytes was associated with the development of hepatic steatosis and the increase of total cholesterol and triglyceride levels [”
BackgroundBoullu-Ciocca, S., Dutour, A., Guillaume, V., Achard, V., Oliver, C., & Grino, M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.197 · Cited by 189
“Fed OF rats showed increases in circulating insulin, glucose, and FFAs compared with controls.”
BackgroundInfluentialMetabolic comorbidities in Cushing's syndrome
Ferraù, F., & Korbonits, M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0354 · Cited by 187
Tomlinson, J. W., Sinha, B., Bujalska, I., Hewison, M., & Stewart, P. M. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020687 · Cited by 187
A physiologic approach to diagnosis of the Cushing syndrome.
Raff, H., & Findling, J. W. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-12-200306170-00010 · Cited by 186
“A groundbreaking study has recently been published describing a transgenic murine model resembling the metabolic syndrome in humans (22).”
Background11β-hydroxysteroid dehydrogenases: changing glucocorticoid action
Seckl, J. R. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.09.001 · Cited by 185
Self-citationMetyrapone as Additive Treatment in Major Depression: A Double-blind and Placebo-Controlled Trial
Jahn, H., Schick, M., Kiefer, F., Kellner, M., Yassouridis, A., & Wiedemann, K. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.12.1235 · Cited by 184
Cooper, M. S., & Stewart, P. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1412 · Cited by 183
Bitter melon ( Momordica charantia L.) bioactive composition and health benefits: A review
Tan, S. P., Kha, T. C., Parks, S. E., & Roach, P. D. (2015) · Food Reviews International · doi:10.1080/87559129.2015.1057843 · Cited by 183
“glucocorticoid hormone, cortisol, can result from the overexpression of 11β-HSD1 and can lead to visceral obesity and insulin resistance.((97)) As a result of such findings, inhibition of 11β-HSD1 has been suggested as a novel therapeutic target for the treatment of obesity and type 2 diabetes.”
BackgroundYu, C.-Y., Mayba, O., Lee, J. V., Tran, J., Harris, C., Speed, T. P., & Wang, J.-C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015188 · Cited by 180
“, have shown that reducing the glucocorticoid signaling in vivo protects the animals from various metabolic disorders and improves their metabolic profiles. Intriguingly, several studies have shown that increasing active glucocorticoid levels specifically in adipocytes can cause metabolic syndrome”
BackgroundCortisol—cause and cure for metabolic syndrome?
Walker, B. R. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01998.x · Cited by 179
Janssen, J. A. M. J. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158178 · Cited by 180
Westerbacka, J., Yki-Järvinen, H., Vehkavaara, S., Häkkinen, A.-M., Andrew, R., Wake, D. J., Seckl, J. R., & Walker, B. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030596 · Cited by 178
Self-citationGlucocorticoid-induced hypertension
Goodwin, J. E., & Geller, D. S. (2011) · Pediatric Nephrology · doi:10.1007/s00467-011-1928-4 · Cited by 178
“This question was elegantly answered by Masuzaki and colleagues who generated a transgenic mouse overexpressing 11β-HSD1 specifically in visceral adipose tissue [ 59 ].”
BackgroundEarly life programming of obesity and metabolic disease
Cottrell, E. C., & Ozanne, S. E. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.11.017 · Cited by 178
Behavioral and physiological characterization of male mice under chronic psychosocial stress
Bartolomucci, A., Pederzani, T., Sacerdote, P., Panerai, A. E., Parmigiani, S., & Palanza, P. (2004) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2003.08.003 · Cited by 176
“(Masuzaki et al., 2001).”
Tejido adiposo: heterogeneidad celular y diversidad funcional
Esteve Ràfols, M. (2014) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2013.03.011 · Cited by 173
Interaction between Corticosterone and Insulin in Obesity: Regulation of Lard Intake and Fat Stores
la Fleur, S. E., Akana, S. F., Manalo, S. L., & Dallman, M. F. (2004) · Endocrinology · doi:10.1210/en.2003-1359 · Cited by 155
Tissue Production of Cortisol by 11β‐Hydroxysteroid Dehydrogenase Type 1 and Metabolic Disease
WALKER, B. R., & ANDREW, R. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1367.012 · Cited by 150
Maniam, J., & Morris, M. J. (2010) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.10.013 · Cited by 172
“Other studies with no stress component reported a strong correlation between upregulation of adipose 11b-HSD1 mRNA expression and the risk of developing obesity in both animal and human models (Masuzaki et al., 2001; Rask et al., 2002).”
BackgroundDesbriere, R., Vuaroqueaux, V., Achard, V., Boullu‐Ciocca, S., Labuhn, M., Dutour, A., & Grino, M. (2006) · Obesity · doi:10.1038/oby.2006.92 · Cited by 156
“Data from rodents provide evidence for a causal role of 11 -HSD-1 in the development of obesity and its complications (2,3).”
Resistin: molecular history and prognosis
Banerjee, R. R., & Lazar, M. A. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0428-9 · Cited by 172
Role of Heme Oxygenase in Inflammation, Insulin-Signalling, Diabetes and Obesity
Ndisang, J. F. (2010) · Mediators of Inflammation · doi:10.1155/2010/359732 · Cited by 172
“[199] H.”
BackgroundWestern Diet: Implications for Brain Function and Behavior
López-Taboada, I., González-Pardo, H., & Conejo, N. M. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.564413 · Cited by 140
“HPA axis dysregulation changes feeding behavior, leading to obesity because of hypercortisolism that increases the intraadipose tissue GRs contributing to metabolic disease (Masuzaki et al., 2001).”
BackgroundGlucocorticoids and Type 2 Diabetes: From Physiology to Pathology
Di Dalmazi, G., Pagotto, U., Pasquali, R., & Vicennati, V. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/525093 · Cited by 168
“Transgenic mice overexpressing 11β-HSD1 selectively in the adipose tissue have been shown to faithfully recapitulate the stigmata of the MetS [96–98], whereas 11β-HSD1-KO mice treated with 11β-HSD1 inhibitors have been reported to be protected from cardiometabolic risks of the obesity [99].”
BackgroundKoch, M. A., & Waldmann, H. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03419-7 · Cited by 167
Laplante, M., Sell, H., MacNaul, K. L., Richard, D., Berger, J. P., & Deshaies, Y. (2003) · Diabetes · doi:10.2337/diabetes.52.2.291 · Cited by 153
“Furthermore, 11 -HSD-1 null mice are resistant to diet-induced insulin resistance (48), whereas transgenic mice overexpressing 11 -HSD-1 exhibit increased corticosterone levels, visceral obesity, and insulinresistant diabetes (49).”
BackgroundAdipose tissue: Cell heterogeneity and functional diversity
Esteve Ràfols, M. (2014) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2014.02.001 · Cited by 166
“For example, transgenic mice overexpressing 11 hydroxysteroid dehydrogenase in WAT have the same enzyme level in several tissues but only develop visceral obesity.(7) Differences between WAT location and expression profile have also been reported in relation to genes implicated in embryonic development, specifically f…”
BackgroundHormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes
Kralisch, S., Klein, J., Lossner, U., Bluher, M., Paschke, R., Stumvoll, M., & Fasshauer, M. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.06211 · Cited by 166
“…the other hand, transgenic overexpression of 11 - hydroxysteroid dehydrogenase type 1 (11 -HSD-1) in fat, which results in increased local levels of corticosterone, is accompanied by various symptoms of the metabolic syndrome including insulin resistance and obesity (Masuzaki et al. 2001).”
Metadata
- Authors
- Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- University of Edinburgh (GB)
- Corresponding author
- Flier, Jeffrey S.
- Venue
- Science
- Published
- 2001-12-07
- Volume
- 294
- Issue
- 5549
- Pages
- 2166-2170
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2117268230
- Cited by
- 1,766
- References
- 34
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 30 · 2023: 19 · 2022: 23 · 2021: 44 · 2020: 34 · 2019: 39 · 2018: 54 · 2017: 52 · 2016: 63 · 2015: 74 · 2014: 72 · 2013: 106 · 2012: 98
- FWCI
- 71.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- visceral obesity, metabolic syndrome, 11β-hydroxysteroid dehydrogenase type 1, glucocorticoids, corticosterone, adipose tissue, transgenic mice, insulin resistance, diabetes mellitus, hyperlipidemia, hyperphagia, leptin, high-fat diet
- MeSH terms
- Abdomen, Adipose Tissue, Animals, Body Composition, Corticosterone, Dietary Fats, Disease Models, Animal, Eating, Humans, Hydroxysteroid Dehydrogenases, Hyperglycemia, Hyperinsulinism, Insulin Resistance, Lipids, Lipoprotein Lipase, Male, Mice, Transgenic, Obesity, Receptors, Glucocorticoid, Viscera, Weight Gain, Adipocytes, Gene Targeting, Leptin, Metabolic Syndrome, 11-beta-Hydroxysteroid Dehydrogenase Type 1, Cell Size, Lipid Metabolism, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.